- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01763710
Neurotoxicity Characterization Study of Nab-paclitaxel Versus Conventional Paclitaxel in Metastatic Breast Cancer (neurabrax)
Neurotoxicity Characterization Phase II Randomized Study of Nab-paclitaxel Versus Conventional Paclitaxel as First-line Therapy of Metastatic HER2-negative Breast Cancer.
Nanomedicines are currently being developed in the treatment of cancer due to their pharmacological advantages over traditional formulations; they provide a shorter infusion time and lower risks of hypersensitivity reactions associated with commonly used solvents.
Nab-paclitaxel is a nanoparticle albumin-bound particle form of paclitaxel that is thought to exploit natural albumin pathways to enhance the selective uptake and accumulation of paclitaxel at the site of the tumour, thus reducing its diffusion to normal tissues.
Nab-paclitaxel has been approved for the treatment of metastatic breast cancer patients who have failed first-line treatment for metastatic disease and for whom standard, anthracycline-containing therapy is not indicated.
SPARC is a cysteine rich acid protein that is overexpressed in a broad proportion of solid tumours. Expression of this protein could sensitize tumour cells to antitumor activity of Nab-paclitaxel, due to its union through albumin-binding to this protein.
First-line clinical trials have been developed with different Nab-paclitaxel regimens and also in combination with different chemotherapies and trastuzumab, showing a high level of efficacy.
Toxicity profile of Nab-paclitaxel is well characterized with significantly less haematological toxicities compared with conventional paclitaxel.
Nab-paclitaxel derived grade III neuropathy is short-lasting and more reversible than conventional paclitaxel-derived neuropathy, probably due to absence of Cremophor solvent, or due to paclitaxel itself.
However there is still a lack of clinical and physiological characterisation of Nab-paclitaxel induced neuropathy.
The current used tools for early detection and continuous evaluation of neurotoxicity are not optimal. Most used toxicity scales are limited, as they do not provide a detailed information of the severity of the neuropathy, its impact on quality of life, or physiopathology mechanisms.
In addition, an inter-individual variability exists in terms of neurotoxicity predisposition when taxanes are used; it could be related to polymorphic differences in genes implicated in transport and metabolism of these drugs.
Study Overview
Status
Conditions
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
-
Madrid, Spain, 28040
- Hospital Clinico San Carlos
-
Madrid, Spain, 28034
- Hospital Ramón y Cajal
-
Madrid, Spain
- Hospital 12 de Octubre
-
Madrid, Spain, 28031
- Hospital Universitario Infanta Leonor
-
-
Madrid
-
Arganda del Rey, Madrid, Spain, 28500
- Hospital Universitario Del Sureste
-
Fuenlabrada, Madrid, Spain, 28942
- Hospital Universitario de Fuenlabrada
-
Getafe, Madrid, Spain, 28905
- Hospital Universitario de Getafe
-
Leganés, Madrid, Spain, 28911
- Hospital Universitario Severo Ochoa
-
Majadahonda, Madrid, Spain, 28222
- Hospital Universitario Puerta de Hierro Majadahonda
-
Parla, Madrid, Spain, 28981
- Hospital Universitario Infanta Cristina
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Women with histologically or cytologically of stage IV breast cancer.
- Non-candidate patient to trastuzumab or lapatinib treatment as not presenting HER2 oncogene amplification.
- Metastatic disease not previously treated with chemotherapy. It is allowed pre-treatment hormone with anti-target or bisphosphonates for advanced disease.
- Measurable or evaluable disease by RECIST criteria.
- Previous sensory neuropathy <= grade 1, according to NCI-CTCAE criteria, due to any reason.
- Age> 18 years.
- Performance status <2 (ECOG).
- At least 12 months after the completion of adjuvant chemotherapy with taxanes to diagnosis of metastatic disease.
- Creatinine <= 1.5mg/dL, AST (SGOT), ALT (SGPT) and alkaline phosphatase <= 2.5 x ULN (hepatic metastases absent) in the 14 days prior to study entry.
- Hemoglobin> 10g/dl, WBC> 3000/mm3, platelets> 100000/mm3 and bilirubin <1.5 mg / dL in the 14 days prior to study entry.
- Women of childbearing potential with negative pregnancy test within 14 days prior to study treatment.
- Patients using adequate contraception throughout the entire duration of the study and until 4 weeks after completion of treatment.
- At least 4 weeks after radiotherapy or major surgery, with complete recovery.
- Life expectancy greater than 12 weeks.
- Patients who are able to meet the requirements of the protocol.
- Patients able to provide with two plasma samples (each sample 5cc) for analyzing polymorphisms.
- Written informed consent.
Exclusion Criteria:
- Prior chemotherapy treatment for metastatic disease.
- Brain metastases.
- Concomitant treatment with hormone therapy or immunotherapy for breast cancer, or during the two weeks prior to inclusion in the study.
- Any concomitant medical or psychiatric illness including active infection.
- History of any malignancy other than breast cancer in the past 5 years except carcinoma or basal cell skin carcinoma or carcinoma in situ of cervix.
- Prior treatment with an investigational drug within the last 2 weeks.
- Known hypersensitivity to paclitaxel or Cremophor.
- Pregnant or breastfeeding.
- Have any acute, subacute or chronic peripheral nerve or spinal cord in grade, at the time of inclusion, greater than or equal to 2 (NCI CTCAE v4.0).
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Diagnostic
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Arm A
Paclitaxel 80 mg/m2 days 1, 8 and 15
|
Paclitaxel 80 mg/m2 days 1, 8 and 15
|
Experimental: Arm B
Nab-paclitaxel 100 mg/m2 days 1, 8 and 15
|
Nab-paclitaxel 100 mg/m2 days 1, 8 and 15
|
Experimental: Arm C
Nab-paclitaxel 150 mg/m2 days 1, 8 and 15
|
Nab-paclitaxel 150 mg/m2 days 1, 8 and 15
|
Experimental: Arm D
Nab-paclitaxel 150 mg/m2 days 1 and 15
|
Nab-paclitaxel 150 mg/m2 days 1 and 15
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
TNS - Total Neuropathy Score
Time Frame: Every 3 months up to 6 months
|
Every 3 months up to 6 months
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Evaluate the incidence of neuropathy induced by study treatment (conventional paclitaxel vs nab-paclitaxel)
Time Frame: Every 3 weeks up to 24 weeks
|
Every 3 weeks up to 24 weeks
|
Evaluate the electromyographic abnormalities and the correlation of these alterations with the assessment of the TNS scale and NCI-CTCAE (Common Toxicity Criteria for Adverse Effects) v4.0
Time Frame: Every 12 weeks up to 24 weeks
|
Every 12 weeks up to 24 weeks
|
Determine the predictive value of genetic variants (SNPs) for the development of neuropathy
Time Frame: In the two weeks before start treatment
|
In the two weeks before start treatment
|
Determine the clinical activity of both treatments (response rate, time to progression)
Time Frame: Every 8-12 weeks up to 24 weeks
|
Every 8-12 weeks up to 24 weeks
|
Determine toxicity profile and safety of study treatments (NCI-CTCAE v4.0)
Time Frame: Every 2 weeks up to 24 weeks
|
Every 2 weeks up to 24 weeks
|
Determine time to neurotoxicity onset
Time Frame: Every 2 weeks up to 24 weeks
|
Every 2 weeks up to 24 weeks
|
Determine time to recovery from neurotoxicity
Time Frame: Every 2 weeks up to 24 weeks
|
Every 2 weeks up to 24 weeks
|
Determine time to progression
Time Frame: Every 8-12 weeks up to 24 weeks
|
Every 8-12 weeks up to 24 weeks
|
Assess quality of live (EORTC QLQ-C30 and EORTC QLQ-CIPN20)
Time Frame: Every 4 weeks up to 24 weeks
|
Every 4 weeks up to 24 weeks
|
Collaborators and Investigators
Sponsor
Investigators
- Study Director: Eva Ciruelos, MD, Hospital 12 de Octubre, Servicio de Oncologia Medica
- Principal Investigator: Noelia Martínez, MD, Hoapital Ramón y Cajal, Servicio de Oncología Médica
- Principal Investigator: Rafael Carrión, MD, Hospital Universitario del Sureste, Servicio de Oncología Médica
- Principal Investigator: José A García Sáenz, MD, Hospital Clínico San Carlos, Servicio de Oncología Médica
- Principal Investigator: María Echarri, Md, Hospital Universitario Severo Ochoa, Servicio de Oncología Médica
- Principal Investigator: Blanca Cantos, MD, Hospital Universitario Puerta de hierro Majadahonda, Servicio de Oncología Médica
- Principal Investigator: Coralía Bueno, MD, Hospital Universitario Infanta Cristina, Servicio de Oncología Médica
- Principal Investigator: Miguel A Lara, MD, Hospital Universitario Infanta Leonor
- Principal Investigator: Santos Enrech, MD, Hospital Universitario de Getafe, Servicio de Oncología Médica
- Principal Investigator: Juan A Guerra, MD, Hospital Universitario de Fuenlabrada
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Chemically-Induced Disorders
- Nervous System Diseases
- Skin Diseases
- Neoplasms
- Neoplasms by Site
- Breast Diseases
- Poisoning
- Breast Neoplasms
- Neurotoxicity Syndromes
- Molecular Mechanisms of Pharmacological Action
- Antineoplastic Agents
- Tubulin Modulators
- Antimitotic Agents
- Mitosis Modulators
- Antineoplastic Agents, Phytogenic
- Paclitaxel
- Albumin-Bound Paclitaxel
Other Study ID Numbers
- ONCOSUR-2012-01
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Breast Cancer
-
Northwestern UniversityEisai Inc.UnknownMale Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Estrogen Receptor-negative Breast Cancer | Progesterone Receptor-negative Breast Cancer | HER2-negative...United States
-
Rutgers, The State University of New JerseyNational Cancer Institute (NCI); Rutgers Cancer Institute of New JerseyActive, not recruitingStage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IIA Breast Cancer | Stage IIB Breast Cancer | Stage IIIC Breast Cancer | Estrogen Receptor-negative Breast Cancer | Progesterone Receptor-negative Breast Cancer | HER2-negative Breast CancerUnited States
-
University of Southern CaliforniaNational Cancer Institute (NCI)TerminatedMale Breast Cancer | Stage IV Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast CancerUnited States
-
University of Southern CaliforniaNational Cancer Institute (NCI)WithdrawnStage IV Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast Cancer
-
University of WashingtonTerminatedBreast Cancer | Breast Cancer Stage I | Breast Cancer Stage II | Breast Cancer Stage III | Breast Cancer Stage IIB | Breast Cancer Stage IIA | Breast Cancer Stage IIIA | Breast Cancer Stage IIIB | Breast Cancer Stage IIIcUnited States
-
CelgeneCompletedBreast Cancer | Metastatic Breast Cancer | Stage IV Breast Cancer | Triple-negative Breast Cancer | Recurrent Breast Cancer | Breast Tumor | Cancer of the Breast | Triple-negative Metastatic Breast Cancer | Estrogen Receptor- Negative Breast Cancer | HER2- Negative Breast Cancer | Progesterone Receptor- Negative...United States, United Kingdom, Italy, Germany, Spain, Canada, Portugal, Australia, Austria, Greece, Brazil, France
-
University of Southern CaliforniaNational Cancer Institute (NCI)TerminatedHER2-positive Breast Cancer | Stage IV Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast CancerUnited States
-
University of WashingtonNational Cancer Institute (NCI)CompletedHER2-positive Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Estrogen Receptor-negative Breast Cancer | Estrogen Receptor-positive Breast Cancer | Progesterone Receptor-negative Breast Cancer | Progesterone Receptor-positive Breast...United States
-
University of California, IrvineNational Cancer Institute (NCI); National Institutes of Health (NIH)CompletedBreast Cancer | HER2-positive Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast Cancer | HER2-negative Breast CancerUnited States
-
University of WashingtonNational Cancer Institute (NCI)CompletedHER2-positive Breast Cancer | Stage IV Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Estrogen Receptor-positive Breast CancerUnited States
Clinical Trials on Paclitaxel 80 mg/m2
-
Hadassah Medical OrganizationUnknownBreast NeoplasmsIsrael
-
Boehringer IngelheimCompletedBreast NeoplasmsHong Kong, Taiwan, United Kingdom, Russian Federation, India, Poland
-
Zhejiang Hisun Pharmaceutical Co. Ltd.Unknown
-
PH Research, S.L.CompletedAdvanced Pancreatic CancerSpain
-
Chengdu Zenitar Biomedical Technology Co., LtdRecruitingStudy of Purinostat Mesylate for Injection in the Treatment of Diffuse Large B-cell Lymphoma (DLBCL)Diffuse Large B Cell Lymphoma,DLBCLChina
-
Hao LongRecruitingChemotherapy | Safety | Biomarker | TislelizumabChina
-
The Netherlands Cancer InstituteRoche Pharma AG; Borstkanker Onderzoek GroepActive, not recruitingBreast Cancer | HER2 PositiveNetherlands
-
Genencell Co. Ltd.Recruiting
-
NanOlogy, LLCUS Biotest, Inc.TerminatedOvarian CarcinomaUnited States
-
University of California, San FranciscoTau Consortium; CBD SolutionsCompletedProgressive Supranuclear Palsy (PSP) | Corticobasal Degeneration (CBD) | Corticobasal Syndrome (CBS) | Primary Four Repeat Tauopathies (4RT)United States